Cell Therapy Sector Remains a Hotspot for Investment in 2026, with Multiple Companies Securing Over RMB 100 Million in Funding

　　【Pharmaceutical Network Industry DynamicsRecently, Caprico Biotechnologies announced the completion of a Pre-A round of financing worth tens of millions of RMB. This round was jointly invested by Huangpu Pharmaceutical Fund and Yabao Pharmaceutical Group, with RayLink Capital serving as the exclusive financial advisor.
 

Caprico Biotechnologies is a company that integrates clinical and research flow reagents,配套的流式细胞仪, and distinctive fluorescence. The Huangpu Medical Fund stated that as cell therapy continues to penetrate clinical applications and people's awareness of immunity gradually increases, flow cytometry will play an increasingly important role in clinical settings.
 

In recent years, with the rapid development of cell immunotherapy technology in China, a wave of enthusiasm for cancer treatment has emerged, attracting numerous companies to actively enter the field. At the same time, capital continues to increase its investment in this track. According to a report, the overall performance of the biopharmaceutical financing market was lackluster in 2022, with the financing amount for cell and gene therapy remaining flat compared to last year, while the number of financing deals saw a significant increase.
 

Since entering 2023, the cell therapy sector has maintained a certain level of activity in financing. According to public reports, apart from Caprico Biotechnologies, numerous companies venturing into the cell therapy field have announced completed financings within the year, with amounts ranging from tens of millions to hundreds of millions of yuan.
 

For example, Gravel Bio announced on September 8 the completion of a 400 million yuan Series B financing round to support the development of the company's Tumor-Infiltrating Lymphocyte (TIL) therapy pipeline. This round of financing was led by a fund under CICC Capital, with participation from Qianhai Ark, Liantuo Investment, Yuanhe Capital, Hefangtian Partnership, and existing shareholders Sherpa Healthcare Partners, Decheng Capital, and Matrix Partners China.
 

Rui Therapeutics announced in mid-July the completion of a Pre-A round of financing worth tens of millions of RMB. This round of financing was led by Shuimu Chunjing Capital, with participation from Zhejiang Fujju Investment. The proceeds will be used for Rui Therapeutics to complete its IND application, advance pipeline products, support investigator-initiated clinical trials (IIT) for existing R&D projects, and develop early-stage pipelines.
 

UCELLO announced at the beginning of June that it had completed a 150-million-yuan A+ round of financing. The funds will be used to accelerate the industrialization of the company's allogeneic universal CAR-T cell therapy products and to advance the new drug application and market launch process. This round of financing was led by Juke Investment, with participation from Guozhong Capital and Penglai Capital. Existing shareholders Guosheng Capital, Jingwei Ventures, and Caprico Biotechnologies continued to increase their investments.
 

Neowise Biotechnology announced in March that it had completed a nearly 200 million yuan A+ round of financing. This round of financing will accelerate the further expansion of its existing TCR-T cell therapy product pipeline and rapidly move towards the clinical stage. The investors in this round include healthcare-focused funds such as Yuanhe Origin, Yuan Yi Capital, GEM, Tonggao Capital, Zhongxin Capital, and Lingjun Venture Capital. Existing shareholder TF Capital continued to increase its investment, and Hoyer Capital served as the exclusive financial advisor for this round of financing.
 

Jiyin Biotechnology announced in early January that it has completed an angel round of financing worth tens of millions of yuan. This round of financing was led by EF Capital, with co-investments from HEC Capital, Shenzhen High-Tech Investment, and Qianhai Honghui Holdings. It is reported that the funds from this round of financing will be used to accelerate the development of the universal cell therapy pipeline and further attract core members with rich experience in the field of cell and gene therapy.
 

　　......
 

Cell therapy has enormous potential and a vast market size. Data shows that the global cell therapy market size was $4.77 billion in 2022, and it is projected to have a compound annual growth rate (CAGR) of 16.5% from 2023 to 2030. With the growing presence of numerous companies and increased investment, it is believed that more effective therapeutic products will be available for clinical use and patients in the future.
 

Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to any person.